• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Overall prognosis of index lung cancer recurrence or of second primary lung cancer in people with non-small cell lung cancer operated with complete resection.非小细胞肺癌完全切除术后患者的指数肺癌复发或第二原发性肺癌的总体预后。
Cochrane Database Syst Rev. 2024 Aug 1;8(8):CD015319. doi: 10.1002/14651858.CD015319.
2
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
3
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer.免疫检查点抑制剂联合铂类化疗对比铂类化疗联合或不联合贝伐珠单抗用于治疗老年人晚期非小细胞肺癌的一线治疗。
Cochrane Database Syst Rev. 2024 Aug 13;8(8):CD015495. doi: 10.1002/14651858.CD015495.
4
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.
5
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法（不包括检查点抑制剂）。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
6
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.早期非小细胞肺癌切除术后的辅助化疗
Cochrane Database Syst Rev. 2015 Mar 2;2015(3):CD011430. doi: 10.1002/14651858.CD011430.
7
Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer.针对非小细胞肺癌引起胸部症状患者的姑息性放疗方案。
Cochrane Database Syst Rev. 2015 Jan 14;1(1):CD002143. doi: 10.1002/14651858.CD002143.pub4.
8
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2015 Oct 5;2015(10):CD006301. doi: 10.1002/14651858.CD006301.pub4.
9
PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer.正电子发射断层显像-计算机断层扫描用于评估疑似可切除非小细胞肺癌患者的纵隔淋巴结受累情况。
Cochrane Database Syst Rev. 2014 Nov 13;2014(11):CD009519. doi: 10.1002/14651858.CD009519.pub2.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中，如果患者出现以下症状和体征，可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.非小细胞肺癌，2022年第3版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南
J Natl Compr Canc Netw. 2022 May;20(5):497-530. doi: 10.6004/jnccn.2022.0025.
2
PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews.PRISMA-S：用于在系统评价中报告文献检索的 PRISMA 声明扩展。
J Med Libr Assoc. 2021 Apr 1;109(2):174-200. doi: 10.5195/jmla.2021.962.
3
Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.根治性治疗非小细胞肺癌（NSCLC）后随访对新发和复发病灶、再治疗和生存的影响：系统评价和荟萃分析。
J Thorac Oncol. 2021 May;16(5):784-797. doi: 10.1016/j.jtho.2021.01.1622. Epub 2021 Feb 12.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.非小细胞肺癌手术后十年复发、第二原发肿瘤或其他肿瘤的风险。
Clin Lung Cancer. 2020 Jul;21(4):333-340. doi: 10.1016/j.cllc.2020.02.011. Epub 2020 Feb 26.
6
GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks.GRADE 指南 28：使用 GRADE 评估预后因素证据：评估识别具有不同绝对风险的患者群体的确定性。
J Clin Epidemiol. 2020 May;121:62-70. doi: 10.1016/j.jclinepi.2019.12.023. Epub 2020 Jan 23.
7
Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline.根治性治疗后肺癌监测：ASCO 指南。
J Clin Oncol. 2020 Mar 1;38(7):753-766. doi: 10.1200/JCO.19.02748. Epub 2019 Dec 12.
8
Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.让我们不要低估 NSCLC 手术后 SPLC 的长期风险。
Lung Cancer. 2019 Nov;137:23-30. doi: 10.1016/j.lungcan.2019.09.001. Epub 2019 Sep 3.
9
A guide to systematic review and meta-analysis of prognostic factor studies.预后因素研究的系统评价与Meta分析指南
BMJ. 2019 Jan 30;364:k4597. doi: 10.1136/bmj.k4597.
10
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies.PROBAST：一种用于评估偏倚风险和预测模型研究适用性的工具。
Ann Intern Med. 2019 Jan 1;170(1):51-58. doi: 10.7326/M18-1376.

非小细胞肺癌完全切除术后患者的指数肺癌复发或第二原发性肺癌的总体预后。

Overall prognosis of index lung cancer recurrence or of second primary lung cancer in people with non-small cell lung cancer operated with complete resection.

机构信息

Department of Chest Diseases and Thoracic Oncology, University Hospital of Besançon, Besançon, France.

EFS, INSERM, UMR RIGHT, Université de Franche-Comté, CHU Besançon, Besancon, France.

出版信息

Cochrane Database Syst Rev. 2024 Aug 1;8(8):CD015319. doi: 10.1002/14651858.CD015319.

DOI:10.1002/14651858.CD015319
PMID:39087518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11292786/
Abstract

This is a protocol for a Cochrane Review (prognosis). The objectives are as follows: We aim to compare overall survival in people with recurrence and second primary lung cancer (SPLC) after lung cancer surgery. If survival differs between those people categorised as having index lung cancer recurrence and those categorised as having SPLC, it might be possible to identify the definition that has the best discriminatory capacity from the various published definitions of these conditions, so that it can be used in future.

摘要

这是一份 Cochrane 综述（预后）的方案。目的如下：我们旨在比较肺癌手术后复发和第二原发性肺癌（SPLC）患者的总生存率。如果将肺癌复发的患者和 SPLC 患者进行分类后，生存率存在差异，则可能可以从这些疾病的各种已发表定义中确定具有最佳区分能力的定义，以便将来使用。